Cue Biopharma, Inc.

NASDAQ:CUE

Biotechnology

Healthcare
$14.10 +1.42%

+$0.38 today

Market cap
$102.43M
Beta
2.53
P/E (TTM)
-6.7
EPS (TTM)
-$4.06
52W Low $4.98High $41.42

Volume 0.21M

Average 0.74M

CUE Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Cue Biopharma, Inc.NASDAQ: CUE

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income declines year over year

Q1 FY2026 net income of $5.18M (cash outflow) fell 57.8% year over year, behind the -51.9% change in trailing-twelve-month net income. Over 3 fiscal years it compounded at -20.5% a year.

Context

  • Net income amounted to 96.9% of revenue in FY2025, down 341.1 pp from a year earlier.
  • Net income grew in size in 0 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 2 analysts of -$83.4M (+213.5%) for the fiscal year ending Dec 2026, a step up from the -34.6% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$5.18M-426.7% QoQ
Last fiscal yearDec 2025
-$26.6M-34.6% YoY
LTMMar 2026
-$19.52M-51.9% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-57.8%+26.3%+84.1 pp
1 year-34.6%+213.5%+248.1 pp
3-year CAGR-20.5%-7.3%+13.3 pp
5-year CAGR+2.5%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
(26.6M) USD
Year-over-year change
+34.6%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How CUE compares with its peers on the latest reported figures

  • CUE's LTM Mar 2026 net income of $19.52M is the 5th largest of the 7 companies compared; the peer median is $30.87M.
  • Its year-over-year change of -51.9% is the 6th highest of 7, against a peer median of +7.2%.
  • Net income amounts to 59.6% of revenue for CUE, versus a peer median of 1070.2%.
CUE Competitors Peer median
Net Income for CUE and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IPSCCentury Therapeutics, Inc.LTM Mar 2026$107.79M +391.1%-58.2%—
OTLKOutlook Therapeutics, Inc.LTM Mar 2026$60.96M -388.6%-1.9%18297.5%
SPRBSpruce Biosciences, Inc.LTM Mar 2026$37.19M -32.9%-5.5%—
NRXPNRx Pharmaceuticals, Inc.LTM Mar 2026$24.54M +1.8%-10.4%1070.2%
CUECue Biopharma, Inc.LTM Mar 2026$19.52M -51.9%-20.5%59.6%
EQEquillium, Inc.LTM Mar 2026$19.06M +36.2%-28.9%—
COEPCoeptis Therapeutics, Inc.LTM Mar 2026$12.72M +12.6%-31.8%899.5%
Peer median (excluding CUE) $30.87M+7.2%-19.7%1070.2%

Competitors are the stored peer set for CUE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(44.16M)(53.01M)(50.73M)(40.67M)(26.6M)
Depreciation & Amortization(1.78M)1.81M3.44M2.35M958K
Deferred Income Tax00000
Stock-Based Compensation11.52M9.5M8.18M6.85M4.74M
Change in Working Capital(4.39M)356K(934K)(4.93M)(3.3M)
Accounts Receivables(1.73M)3.09M(1.64M)753K(6.5M)
Inventory00000
Accounts Payables520.4K83K770K(678K)1.13M
Other Working Capital(3.18M)(2.81M)(63K)(5M)2.08M
Other Non-Cash Items(26.13K)(454K)90K74K2.51M
Operating Cash Flow(38.84M)(41.81M)(39.96M)(36.33M)(21.69M)
Capital Expenditures(913.04K)(171K)0(66K)(177K)
Acquisitions (Net)000040K
Purchases of Investments0(29.45M)00(16.5M)
Sales of Investments10M5M25M016.5M
Other Investing Activities21.55K6K2K98K212K
Investing Cash Flow9.11M(24.61M)25M32K75K
Debt Repayment010M(2M)(4M)(4.5M)
Common Stock Issued17.38M39.3M13.39M14.22M30.79M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities1.85M4.36M473K18K0
Financing Cash Flow19.23M53.66M11.86M10.24M26.29M
Effect of Forex Changes00000
Net Change in Cash(10.5M)(12.76M)(3.1M)(26.05M)4.68M
Free Cash Flow(39.75M)(41.98M)(39.96M)(36.4M)(21.86M)

Cue Biopharma, Inc.

NASDAQ:CUE

Intrinsic Alpha fair value

Locked

Current Price

$14.10

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.